Transcatheter Pulmonary Valve Market: Market Size & Forecast 2026

The transcatheter pulmonary valve market represents a critical subset of the global heart valve prostheses sector, which reached approximately $8.9 billion in recent years. These devices are delivered via catheter-based techniques, offering a less invasive option for patients with pulmonary valve disease, particularly those with congenital heart defects such as tetralogy of Fallot or prior surgical repairs with dysfunctional right ventricular outflow tracts. The market is projected to reach roughly $30 billion by 2035, reflecting a compound annual growth rate estimated between 7.5% and 12.9%.

• •Market size estimated at $8.9 billion in 2025, with projected growth toward $30 billion by 2035
• •Primarily addresses congenital heart disease patients with dysfunctional pulmonary valves and right ventricular outflow tract complications
• •Represents a shift from traditional surgical valve replacement toward minimally invasive transcatheter approaches

The market is expanding as clinical evidence supporting transcatheter pulmonary valve implantation (TPVI) continues to accumulate across diverse patient populations. The development of balloon-expandable and self-expanding valve systems has broadened the eligible patient pool beyond those with standard anatomies. Advanced imaging protocols, including 4D-CT screening, are improving patient selection and procedural planning, further accelerating adoption.

• •Growing adoption of TPVR for complex biological valve degenerations, including valve-in-valve procedures for carcinoid heart disease and other high-risk populations
• •Geographic expansion into low- and middle-income nations through corporate partnerships and registry-based tracking programs
• •FDA registries and commercial market-tracking systems documenting increasing procedural volumes worldwide

The market is broadly segmented by device type, including self-expanding valves such as the Venus P-valve and balloon-expandable systems like Edwards Sapien. Patient populations are primarily divided between congenital heart disease patients and those with acquired valve degeneration. Geographically, adoption has been strongest in North America and Europe, with increasing penetration into emerging markets in Africa and Asia.

• •Device categories include self-expanding (e.g., Venus P-valve) and balloon-expandable (e.g., Sapien, Harmony) transcatheter pulmonary valve systems
• •Patient segments span congenital heart disease, post-surgical right ventricular outflow tract dysfunction, and acquired valve degeneration such as carcinoid heart disease
• •Expanding geographic footprint documented from established markets into low- and middle-income nations

What are the recent trends and outlook?

The market is expected to maintain strong growth momentum through 2035, supported by ongoing technological refinements and expanding clinical indications. The structural heart disease device sector broadly is projected for rapid adoption increases through 2030, with specialized segments like transcatheter pulmonary valves playing an increasingly prominent role. Continued improvements in imaging guidance, device design, and evidence generation are likely to further broaden the eligible patient population and drive procedural volume growth.

• •Projected sustained CAGR of 10.2% through 2035, positioning the market near $30 billion as transcatheter approaches become standard of care
• •Rising adoption of 4D-CT and dynamic imaging protocols to improve procedural planning and expand the addressable patient population
• •Potential for new device entrants and pipeline innovations to further disrupt the surgical-to-transcatheter transition